liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden; Public Health Agency of Sweden, Sweden.
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden.
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2024 (English)In: The Lancet - Infectious diseases, ISSN 1473-3099, E-ISSN 1474-4457, Vol. 24, no 2, p. e80-e81Article in journal, Letter (Refereed) Published
Abstract [en]

Conflict of interest statement

pCMV-dR8·2 dvpr was a gift from Bob Weinberg (Addgene plasmid # 8455; http://n2t.net/addgene:8455; RRID:Addgene_8455). pBOBI-FLuc was a gift from David Nemazee (Addgene plasmid # 170674; http://n2t.net/addgene:170674; RRID: Addgene_170674). We acknowledge the G2P-UK National Virology consortium funded by MRC/UKRI (grant ref: MR/W005611/1) and the Barclay Lab at Imperial College for providing the XBB.1.5 spike plasmid. We gratefully acknowledge all data contributors, ie, the authors and their originating laboratories responsible for obtaining the specimens, and their submitting laboratories that generated the genetic sequence and metadata and shared via the GISAID Initiative the data on which part of this research is based. This project was supported by funding from the Jonas and Christina af Jochnick Foundation, Region Stockholm, SciLifeLab/Knut and Alice Wallenberg Foundation, SciLifeLab's Pandemic Laboratory Preparedness program (VC-2022–0028) and from the Erling Persson Foundation (2021 0125). DJS has served as a consultant for AstraZeneca outside this comment. All other authors declare no competing interests. UM and OB contributed equally and share first authorship; DJS and CT jointly supervised the work and share last authorship.

Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 24, no 2, p. e80-e81
National Category
Immunology in the Medical Area
Identifiers
URN: urn:nbn:se:liu:diva-212909DOI: 10.1016/s1473-3099(23)00779-xISI: 001178078500001PubMedID: 38190833Scopus ID: 2-s2.0-85182978994OAI: oai:DiVA.org:liu-212909DiVA, id: diva2:1950835
Funder
Knut and Alice Wallenberg FoundationStockholm County CouncilScience for Life Laboratory, SciLifeLabFamiljen Erling-Perssons StiftelseAvailable from: 2025-04-09 Created: 2025-04-09 Last updated: 2025-08-18

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Klingström, Jonas

Search in DiVA

By author/editor
Klingström, Jonas
By organisation
Division of Molecular Medicine and VirologyFaculty of Medicine and Health Sciences
In the same journal
The Lancet - Infectious diseases
Immunology in the Medical Area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 54 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf